Schoenberg Mark: insider trades.
Schoenberg Mark reported 4 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 3 sales ($3.3M), across 1 company.
- Transactions
- 4
- Purchases (P)
- 0
- Sales (S)
- 3
- Companies
- 1
- Name as filed
- Schoenberg Mark
Companies
| Company | Relationship | Transactions |
|---|---|---|
| UroGen Pharma Ltd. (URGN) | Officer · Chief Medical Officer | 4 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | UroGen Pharma Ltd. | S | 871 | $42.92 | 59,882 | Form 4 |
| 2026-09-07 | UroGen Pharma Ltd. | M | 1,667 | — | 60,753 | Form 4 |
| 2026-08-20 | UroGen Pharma Ltd. | S | 60,677 | $47.05 | 59,086 | Form 4 |
| 2026-07-09 | UroGen Pharma Ltd. | S | 10,000 | $40 | 119,763 | Form 4 |
Questions
What stock did Schoenberg Mark buy or sell?
Schoenberg Mark reported 4 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 3 sales ($3.3M), across 1 company.
Is Schoenberg Mark the same person as other filers with this name?
This page covers SEC CIK 1763581 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/schoenberg-mark-1763581.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.